乳腺癌中免疫检查点抑制剂概述
An overview of immune checkpoint inhibitors in breast cancer.
作者信息
Miglietta Federica, Cona Maria Silvia, Dieci Maria Vittoria, Guarneri Valentina, La Verde Nicla
机构信息
Department of Surgery, Oncology and Gastroenterology, University of Padova, 35122 Padova, Italy.
Division of Oncology 2, Istituto Oncologico Veneto IRCCS, 35128 Padova, Italy.
出版信息
Explor Target Antitumor Ther. 2020;1(6):452-472. doi: 10.37349/etat.2020.00029. Epub 2020 Dec 28.
Abstract
Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.
摘要
虽然传统上乳腺癌不被认为是一种免疫原性肿瘤，但免疫疗法与化疗的联合最近已成为晚期三阴性亚型的一种新型治疗选择，并且其他类似的免疫检查点抑制剂与化疗的联合有望在不久的将来成为新辅助治疗的一部分。此外，免疫检查点阻断与多种生物制剂联合使用，包括抗HER2药物、CDK 4/6抑制剂、PARP抑制剂，已观察到令人鼓舞的结果。本综述总结了来自临床试验的现有证据，这些证据涉及免疫检查点抑制剂在晚期和早期乳腺癌治疗中的作用。
相似文献
1
An overview of immune checkpoint inhibitors in breast cancer.乳腺癌中免疫检查点抑制剂概述
Explor Target Antitumor Ther. 2020;1(6):452-472. doi: 10.37349/etat.2020.00029. Epub 2020 Dec 28.
2
Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.将免疫疗法融入三阴性乳腺癌患者的治疗格局中。
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_351186.
3
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.免疫检查点抑制剂在乳腺癌治疗中的新作用。
Expert Opin Investig Drugs. 2022 Jun;31(6):531-548. doi: 10.1080/13543784.2022.1986002. Epub 2021 Oct 11.
4
Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.新兴策略：PARP抑制剂与免疫检查点阻断剂联合用于BRCA1和BRCA2突变相关及三阴性乳腺癌
Breast Cancer Res Treat. 2023 Jan;197(1):51-56. doi: 10.1007/s10549-022-06780-4. Epub 2022 Nov 1.
5
Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.免疫检查点抑制剂治疗三阴性乳腺癌：从免疫机制到临床证据。
Int Immunopharmacol. 2021 Sep;98:107876. doi: 10.1016/j.intimp.2021.107876. Epub 2021 Jun 17.
6
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects.免疫检查点抑制剂在三阴性乳腺癌治疗中的应用：前景广阔。
Front Oncol. 2021 Feb 25;10:600573. doi: 10.3389/fonc.2020.600573. eCollection 2020.
7
Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.早期三阴性乳腺癌免疫检查点抑制的进展
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1071-1084. doi: 10.1080/14737140.2023.2262764. Epub 2023 Oct 26.
8
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.免疫疗法在三阴性乳腺癌患者中的应用进展与困境。
Expert Opin Investig Drugs. 2022 Jun;31(6):567-591. doi: 10.1080/13543784.2022.2049232. Epub 2022 Mar 9.
9
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.KEYNOTE-522、IMpassion031 和 GeparNUEVO：改变早期三阴性乳腺癌新辅助免疫检查点抑制剂的范式。
Future Oncol. 2022 Jun;18(18):2301-2309. doi: 10.2217/fon-2021-1647. Epub 2022 Apr 5.
10
Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.免疫检查点抑制剂和乳腺癌的新型免疫治疗方法。
Curr Oncol Rep. 2022 Dec;24(12):1801-1819. doi: 10.1007/s11912-022-01339-4. Epub 2022 Oct 18.
引用本文的文献
1
Unusual Case of Papillary Carcinoma of the Breast.乳腺乳头状癌罕见病例
Cureus. 2024 Jul 1;16(7):e63568. doi: 10.7759/cureus.63568. eCollection 2024 Jul.
2
Neoadjuvant radiotherapy in ER, HER2, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy.基于人源化肿瘤小鼠的 ER、HER2 和三阴性乳腺癌新辅助放疗增强抗 PD-L1 治疗效果。
Front Immunol. 2024 Apr 29;15:1355130. doi: 10.3389/fimmu.2024.1355130. eCollection 2024.
3
Herpesvirus entry mediator as a potential biomarker in breast cancer compared with conventional cytotoxic T‑lymphocyte‑associated antigen 4.与传统细胞毒性T淋巴细胞相关抗原4相比，疱疹病毒进入介质作为乳腺癌潜在生物标志物的研究
Biomed Rep. 2023 Jul 17;19(2):56. doi: 10.3892/br.2023.1638. eCollection 2023 Aug.
4
Innovations and Challenges in Breast Cancer Care: A Review.乳腺癌护理的创新与挑战：综述
Medicina (Kaunas). 2023 May 16;59(5):957. doi: 10.3390/medicina59050957.
5
Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells.定义乳腺癌中新免疫治疗方法的出现：髓系来源抑制细胞的作用。
Int J Mol Sci. 2023 Mar 8;24(6):5208. doi: 10.3390/ijms24065208.
本文引用的文献
1
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.三阴性、早期高危及局部晚期乳腺癌新辅助治疗（无论是否联合阿替利珠单抗）的病理完全缓解（pCR）：NeoTRIP米开朗基罗随机研究
Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. Epub 2022 Feb 17.
2
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.Luminal B 型乳腺癌的新辅助化疗和免疫治疗：GIADA 试验的 II 期结果。
Clin Cancer Res. 2022 Jan 15;28(2):308-317. doi: 10.1158/1078-0432.CCR-21-2260. Epub 2021 Oct 19.
3
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
4
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
5
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.一线帕博利珠单抗治疗 PD-L1 表达≥50%的 NSCLC 患者的基线 BMI 及治疗期间 BMI 变化：一项多中心研究及外部验证。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001403.
6
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.早期三阴性乳腺癌患者新辅助阿替利珠单抗联合序贯纳武利尤单抗和基于蒽环类的化疗与安慰剂和化疗相比：一项随机、双盲、III 期试验（IMpassion031）。
Lancet. 2020 Oct 10;396(10257):1090-1100. doi: 10.1016/S0140-6736(20)31953-X. Epub 2020 Sep 20.
7
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.ER+/HER2- 乳腺癌中的肿瘤浸润淋巴细胞（TILs）。
Breast Cancer Res Treat. 2020 Sep;183(2):347-354. doi: 10.1007/s10549-020-05771-7. Epub 2020 Jul 3.
8
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer.ICON：一项评价免疫化疗联合伊匹单抗和纳武单抗治疗转移性激素受体阳性乳腺癌患者的随机 IIb 期研究。
J Transl Med. 2020 Jul 3;18(1):269. doi: 10.1186/s12967-020-02421-w.
9
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.帕博利珠单抗联合化疗作为高危早期三阴性乳腺癌的新辅助治疗：来自 1b 期开放标签、多队列 KEYNOTE-173 研究的结果。
Ann Oncol. 2020 May;31(5):569-581. doi: 10.1016/j.annonc.2020.01.072. Epub 2020 Feb 14.
10
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
Zotero 插件